European Companies Search Engine
UK funding (£1,131,818): Novel Biocatalysts for Sustainable Manufacture of Pharmaceuticals Ukri1 Mar 2025 UK Research and Innovation, United Kingdom
Overview
Text
Novel Biocatalysts for Sustainable Manufacture of Pharmaceuticals
| Abstract | ErebaGen harnesses chemistry from Nature and its project aims to transform hazardous chemical manufacture through the use of sustainable biological processes. The innovation focus and need is aromatic nitration, a critical chemical step in production of numerous pharmaceutical intermediates. This reaction proceeds rapidly, generates heat, can get out of control risking explosion and formation of unwanted by-products. The process uses hazardous chemicals such as concentrated acid, with associated risks of disposal or leaching. Despite this ~20% of all synthetic pharmaceutical intermediate processes involve nitration. Consequently many are produced abroad, or by multi-step synthetic routes to avoid nitration, increasing cost and time. ErebaGen is responding to the need using our innovative technology platform that harnesses bacterial enzymes evolved by nature over millions of years. Distinctively ErebaGen uses a patented activator to switch on specialised metabolism, that is the synthetic processes not required for survival of the microbes.. This gives ErebaGen a competitive advantage: access to a large, chemically diverse, promiscuous pool of enzymes with flexible substrate tolerance. It is combined with bioinformatics, genomic and chemical analysis and automation. The intellectual property comprises the patented activator and substantial confidential know-how including proprietary software Customers are pharma/biotech companies but our innovations have broad application in agrochemicals, flavours and fragrances, dyes and fine chemicals; the project could open up these markets. ErebaGen's approach can be expanded to a range of other hazardous/inefficient chemical processes. The project brings together a diverse, experienced team from Erebagen, partner CPI and subcontractors National Physical Laboratory, Peritus Regulatory and Sterling Pharma, plus individual experts. We have a two year project plan to demonstrate that enzymatic aromatic nitration is a cost-effective, sustainable alternative to chemical nitration. Performance measurements and comparative assessment will assess this potentially transformational alternative to traditional synthesis. The project deliverables will help ErebaGen secure higher value partnerships, which will take its innovation through to market. |
| Category | Collaborative R&D |
| Reference | 10141017 |
| Status | Active |
| Funded period start | 01/03/2025 |
| Funded period end | 28/02/2027 |
| Funded value | £1,131,818.00 |
| Source | https://gtr.ukri.org/projects?ref=10141017 |
Participating Organisations
| EREBAGEN LTD |
£866,314.00 |
| CENTRE FOR PROCESS INNOVATION LIMITED |
£265,504.00 |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Erebagen Ltd., Kidlington.
The visualizations for "Erebagen Ltd. - UK funding (£1,131,818): Novel Biocatalysts for Sustainable Manufacture of Pharmaceuticals"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
